Cladribine + BEAC

Cladribine + BEAC is a combination chemotherapy regimen combining Cladribine with the BEAC regimen components: BCNU (carmustine), Etoposide, Ara-C (cytarabine), and Cyclophosphamide. Cladribine is an antimetabolite drug that interferes with DNA, preventing cancer cell growth and multiplication. It is used for hairy cell leukemia, B-cell chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma, and acute myeloid leukemia. BCNU (carmustine) and Cyclophosphamide are alkylating agents that damage DNA. Etoposide is a topoisomerase II inhibitor that also interferes with DNA replication. Cytarabine is another antimetabolite (a cytidine analog) that disrupts DNA synthesis. Based on its components, this combination is likely used as an intensive chemotherapy regimen, potentially for refractory or relapsed hematologic malignancies or in the context of stem cell transplantation. While Cladribine is known to be used in various combinations (like CMC and CLAG), specific details or clinical trial information on the Cladribine + BEAC combination were not explicitly available in the provided text. Common side effects associated with cladribine include bone marrow suppression (neutropenia, thrombocytopenia, anemia), infections, fatigue, fever, kidney problems, and neurological issues. Combining it with the BEAC regimen would likely result in a broad range of significant chemotherapy side effects typical of these agents.